A Phase 1, Open-label, Multiple-dose, Single Centre Study to Investigate the Effect of Administration of CAZ-AVI and CXL on the Intestinal Flora of Healthy Volunteers.

Trial Profile

A Phase 1, Open-label, Multiple-dose, Single Centre Study to Investigate the Effect of Administration of CAZ-AVI and CXL on the Intestinal Flora of Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2015

At a glance

  • Drugs Avibactam/ceftaroline fosamil (Primary) ; Avibactam/ceftazidime (Primary)
  • Indications Bacterial infections; Gram-negative infections; Intra-abdominal infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial infections; Systemic inflammatory response syndrome; Urinary tract infections
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 02 Apr 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
    • 18 Feb 2014 Planned number of patients changed from 28 to 30, as per ClinicalTrials.gov record.
    • 18 Feb 2014 Planned End Date changed from 1 Jan 2014 to 1 Mar 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top